3月25日 - ** 生物技术公司Humacyte HUMA.O在发布股票发行消息后，盘后股价下跌23.5%，至2.20美元
** 总部位于北卡罗来纳州达勒姆的公司宣布 (link) 拟议发行股票，但未披露交易规模
** 该公司打算将募集资金净额用于资助其用于治疗血管极度损伤患者的植入物 Symvess 的商业化。
** TD Cowen、巴克莱银行和 BTIG 作为账簿管理人
** 根据伦敦证券交易所的数据，该公司已发行股票约 1.2265 亿股，市值约 3.53 亿美元。
** HUMA 股价周二收盘下跌 13.4%，报 2.88 美元。年初至今，股价下跌了 43
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.